retatrutide pronunciation Safety, Side Effects & Provider Use Retatrutide Results: 28.3% Weight Loss
Description
The first head-to-head study of the two drugs for obesity, SURMOUNT-5 , was published in The New England Journal of Medicine in May 2025
Tirzepatide achieves 20 to 22 percent weight loss in phase 3 data, making it a more direct comparison to retatrutide than semaglutide
They also establish shelf life and proper storage requirements
GLP-1RAs and SGLT-2is both have the ability to penetrate damaged basement membranes and tight junctions (Figure 5)
Patients are prescribed customized dosing plans not pre-filled regimens and have ongoing access to adjust their program based on tolerance and progress
Sun, Y., Liu, B., Snetselaar, L
